{"title": "Merck's ISENTRESS\u00ae (raltegravir) Demonstrated Durable Reductions in HIV-1 Viral Load and Sustained Tolerability At T", "author": null, "url": "https://www.fiercepharma.com/pharma/merck-s-isentress-r-raltegravir-demonstrated-durable-reductions-hiv-1-viral-load-and", "hostname": "fiercepharma.com", "description": "BOSTON--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new Phase III data showed that adult patients with HIV-1 infection maintained | BOSTON--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new Phase III data showed that adult patients with HIV-1 infection maintained", "sitename": "FiercePharma", "date": "2011-03-01", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}